Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...